Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Intelligent BIO Solutions Inc. INBS

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$4.2M
▲ 38.1% YoY
$-12.4M
$-12.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Intelligent Bio Solutions Inc. and its wholly owned Delaware subsidiary, GBS Operations Inc., were each formed on December 5, 2016, under the laws of the state of Delaware. Our headquarters are in New York City. Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. The Company operates globally with the objective of providing innovative and accessible solutions that improve the quality of life. On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited (“IFP”), a company registered in England and Wales.

Written from the business description in Intelligent Bio Solutions Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 19 August 2026. Every sentence was checked against that document before publication.

Growth

USD 4.2M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 4.2 · Net income -12.4
2M3M-5M-10M
201920222025
Compound annual growth
+49.7%
+16.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +16.3% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−296 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -299.1% · Net -295.8%
-500%-1000%-1500%
201920222025
ROE
FY2025 · ROE -292.3%
-100%-200%
201920222025
Three returns, three denominators.

Each USD of equity lost 292 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -12.1
-5M-10M
201920222025

Total assetsUSD 11.9M
EquityUSD 5.5M
CashUSD 4.0M
Gross debtUSD 0.00
Net debtUSD -4.0M
Current ratio1.44×

The company holds more cash than debt.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
INBS, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0◌◌
Income tax $B◌◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0◌◌◌◌
EPS, diluted $−8.44−20.04−6.38−127.00−11.33−0.68−0.37
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %−292.3−186.6−167.5−204.0−76.6——
Shares out B0.000.010.000.000.010.010.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 32 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 15 checks were skipped: cost of revenue is not tagged before 2022. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image